Search company, investor...

OcuNexus Therapeutics

Founded Year



Unattributed | Alive

Total Raised


Last Raised

$9.13M | 2 yrs ago

About OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.

Headquarters Location

12520 High Bluff Drive Suite 350

San Diego, California, 92130,

United States


Missing: OcuNexus Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: OcuNexus Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing OcuNexus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OcuNexus Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

OcuNexus Therapeutics Patents

OcuNexus Therapeutics has filed 50 patents.

The 3 most popular patent topics include:

  • Ion channels
  • Diseases of the eye and adnexa
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Ion channels, Clusters of differentiation, G protein coupled receptors, Integral membrane proteins


Application Date


Grant Date



Related Topics

Transcription factors, Ion channels, Clusters of differentiation, G protein coupled receptors, Integral membrane proteins



Latest OcuNexus Therapeutics News

Persistent Corneal Epithelial Defects Therapeutics Market Size Anticipated to Boost at a CAGR of 18.69% for the Study Period 2018-2030 | DelveInsight

Oct 12, 2021

| DelveInsight The Persistent Corneal Epithelial Defects pipeline therapies expected to get launched in the forecasted period include Nexagon, ST266, RGN-259, REC-0559, and others. These are expected to create a positive shift in the Persistent Corneal Epithelial Defects market during the forecast period (2021-2030). News provided by Share this article Share this article LAS VEGAS, Oct. 12, 2021 /PRNewswire/ -- DelveInsight's Persistent Corneal Epithelial Defects (PEDs or PCEDs) Market  report offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). As per DelveInsight's estimate, the total Persistent Corneal Epithelial Defects incident cases in 2020 were reported to be 241,452 in the 7MM. DelveInsight estimates that PCED affects males more as compared to females. The PCED therapy market space is monopolized by aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. The Persistent Corneal Epithelial Defects therapeutic market size appears to be dominated by the United States in 2020, worth USD 83.9 million. Key pharmaceutical and biotech companies actively engaged in the Persistent Corneal Epithelial Defects market space include OcuNexus Therapeutics, Eyevance Pharmaceuticals, and Noveome Biotherapeutics, among others. The Persistent Corneal Epithelial Defects pipeline therapies expected to launch in the forecasted period (2021-2030) include Nexagon, ST266, RGN-259, REC-0559, and others. The anticipated launch of the pipeline therapies is expected to create a positive shift in the market during the forecast period (2021-2030). Nexagon (OcuNexus Therapeutics, Eyevance Pharmaceuticals) is a first-in-class natural, antisense therapy that downregulates the cell membrane hemichannel forming protein, connexin43 (Cx43). The demand for novel therapies with the absence of key players led to the boosted R&D from the academic-industry partnership that led to the prompting of open innovation and prioritizing the targeting of PED. Novel therapies being investigated recently are beginning to show promise in the treatment of the nonhealing corneal epithelium. Download Persistent Corneal Epithelial Defects Market Snapshot report to understand which Persistent Corneal Epithelial Defects drug is going to capture the maximum market share @  Persistent Corneal Epithelial Defects Therapy Market Analysis and Forecast  Persistent Corneal Epithelial Defects: Disease Overview Persistent Corneal Epithelial Defects (PCED/ PED) are characterized by the failure of the rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Persistent Corneal Epithelial Defects Epidemiological Segmentation DelveInsight's Persistent Corneal Epithelial Defects Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into: Total  Persistent Corneal Epithelial Defects Incident Cases  Gender-specific PCED Incidence  Etiology-specific  Persistent Corneal Epithelial Defects Incidence  Understand how Persistent Corneal Epithelial Defects Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Persistent Corneal Epithelial Defects Epidemiology Market Report Summary The current approaches include aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. Membrane grafting, autologous serum, scleral contact lenses, and others are available for relapse cases. Persistent epithelial defects of the cornea can be challenging to even the experienced ophthalmologist. Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is essential to treat the underlying causative condition, including infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. In individuals with PCEDs, there is a high risk of infection or further injury resulting in permanent vision loss due to corneal scarring, infection, neovascularization, and incomplete wound healing. The current PCED therapy market has several unmet needs in the form of a lack of adequate and curative therapies that can heal or reverse the damage to the cornea. Several pharmaceutical and biotech companies such as OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and several others are working to keep the market growth steady, showcasing an encouraging future picture. DelveInsight estimates that with an entry of pharmaceutical pharma players and the expected launch of novel therapies, the futuristic outlook of the PCED market is anticipated to be promising during the next decade. Besides, a better understanding of the condition of increased healthcare expenditure and funding from international organizations shall further add to the growth of the Persistent Corneal Epithelial Defects market share. Persistent Corneal Epithelial Defects Pipeline Therapies in focus in the report analysis Nexagon: OcuNexus Therapeutics Persistent Corneal Epithelial Defects Market Dynamics Persistent Corneal Epithelial Defects Market to grow due to rising prevalence and increased awareness about the PED and its association with other diseases and its detection. Identifying potential targets, orphan designations, market exclusivity, support from various organizations are attracting the companies to develop novel therapies, which may increase the future Persistent Corneal Epithelial Defects market growth. Nevertheless, the growth of the Persistent Corneal Epithelial Defects Market may be hindered by the poor response rate and various side effects of the available treatment option. Also, stringent regulatory procedures by regulatory authorities on medication and devices are hampering the persistent epithelial defects treatments market.

OcuNexus Therapeutics Frequently Asked Questions (FAQ)

  • When was OcuNexus Therapeutics founded?

    OcuNexus Therapeutics was founded in 2005.

  • Where is OcuNexus Therapeutics's headquarters?

    OcuNexus Therapeutics's headquarters is located at 12520 High Bluff Drive, San Diego.

  • What is OcuNexus Therapeutics's latest funding round?

    OcuNexus Therapeutics's latest funding round is Unattributed.

  • How much did OcuNexus Therapeutics raise?

    OcuNexus Therapeutics raised a total of $69.8M.

  • Who are the investors of OcuNexus Therapeutics?

    Investors of OcuNexus Therapeutics include GBS Venture Partners, Domain Associates, BioPacific Investors and Square 1 Bank.

  • Who are OcuNexus Therapeutics's competitors?

    Competitors of OcuNexus Therapeutics include Adhezion Biomedical, Lead Pharma, Momenta Pharmaceuticals, Histogenics, Regentis Biomaterials, Adello Biologics, InflaRx, OcuCure Therapeutics, FirstString Research, Merus and 26 more.

Compare OcuNexus Therapeutics to Competitors

Plurogen Therapeutics

PluroGen Therapeutics provides clinically advanced and advantaged burn, wound and skin care products. The company works closely with doctors, nurses, patients and healthcare institutions to provide the best products for burn, wound and skin care to help people have a better quality of life. The Company's primary platform is its core PluroGel surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products.


AugmentRx has developed a tissue bulking agent to treat stress urinary incontinence. The SOLVE injectable product aims to provide a fully viable alternative to slings, surgical procedures and inferior shorter-acting bulking agents. Per AugmentRx, it is bioinert, non-antigenic, non-migratory, permanent, easy-to-inject, and more affordable and aims to provide long-lasting, sustainable tissue volume.


Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.


CartiCure is a MedTech company for tissue engineering; developing innovating technology for cartilage repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.nCarticure was established in 2005 and is currently based on the premises of the NGT High-Tech Incubator in Nazareth, Israel; all scientific work as well as on-going animal trials are being conducted at the Faculty of Medicine at Technion-Israel Institute of Technology in Haifa, Israel.


Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n

FirstString Research

FirstString is a biopharmaceutical company dedicated to discovering therapies for inflammation-based medical conditions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.